Application of arginine in preparation of anticarcinogen as synergist of chemotherapeutic drug

Abstract

The chemotherapeutic drug is cisplatin. The invention discloses application of arginine in preparation of an anticarcinogen as a synergist of a chemotherapeutic drug. An in-vitro cell experiment result shows that when the arginine and the cisplatin are used jointly, an inhibiting action on a human colonic adenocarcinoma cell HT29 can be improved remarkably, and a synergistic action can be achieved. Under the condition of the same inhibiting effect, the dosage of the cisplatin is lowered, and thus, potential adverse reactions of the cisplatin can be reduced effectively.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of arginine as a chemotherapeutic synergist in the preparation of anticancer drugs. Background technique [0002] Colon cancer is one of the most common malignant tumors, and its morbidity and mortality are increasing year by year. Since there is no exact etiology for colon cancer, the pathogenesis remains inconclusive. Most colon cancer patients have developed to the middle and late stages when they are diagnosed, and chemotherapy drugs are needed to inhibit tumor growth and prolong survival time. As a representative drug in the field of inorganic medicinal chemistry, cisplatin has been approved for use by the U.S. Food and Drug Administration (FDA) in 1978. Because of its broad anticancer spectrum and strong effect, it has been used for ovarian cancer and testicular cancer. It is one of the most widely clinically used broad-spectrum anticancer drugs for ...

AI Technical Summary

Problems solved by technology

At present, there is no report on the effect of arginine combined with cisplatin on increasing the chemosensitivity of cisplatin

Images